Table 1 Study information included in the meta-analysis
From: Viral infection and glioma: a meta-analysis of prognosis
study | year | region | virus | grade | method | mark | purpose | N | positive | negative | M or U | comparison | effect size | HR | LL | UL | P value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Han,S | 2018 | China | CMV | GBM | IF | gB | OS | 68 | 33 | 35 | U | P VS N | HR | 1 | 0.11 | 9.22 | 0.995 |
IF | gH | OS | 68 | 29 | 39 | U | P VS N | HR | 0.73 | 0.08 | 6.47 | 0.7689 | |||||
Yang, C. F. | 2017 | China | GBM | PCR | UL73 | OS | 116 | 9 | 107 | M | P VS N | HR | 1.661 | 0.771 | 3.575 | 0.195 | |
PFS | 116 | 9 | 107 | M | P VS N | HR | 1.761 | 0.86 | 3.603 | 0.122 | |||||||
Bahador, M. | 2017 | Norway | GBM | IHC | IE1 | OS | 172 | 65 | 107 | M | P VS N | HR | 0.845 | 0.53 | 1.35 | 0.48 | |
Ding, D. | 2014 | China | glioma | IHC | IE1-72 | PFS | 67 | 51 | 16 | M | P VS N | HR | 1.068 | 0.518 | 2.2 | 0.859 | |
IHC | PP65 | PFS | 67 | 44 | 23 | M | P VS N | HR | 0.953 | 0.51 | 1.78 | 0.88 | |||||
PCR | UL55 | PFS | 67 | 35 | 32 | M | P VS N | HR | 0.847 | 0.475 | 1.511 | 0.574 | |||||
Stragliotto, G. | 2013 | Sweden | GBM | OS | M | H VS L | HR | 6.61 | 1.36 | 32.1 | 0.0192 | ||||||
Rahbar, A. | 2013 | Sweden | GBM | IHC | IEA | OS | 75 | 11 | 64 | M | H VS L | HR | 2.2 | 1 | 4.38 | 0.036 | |
PFS | H VS L | HR | 1.778 | 0.8902 | 3.5512 | 0.103 | |||||||||||
IHC | LA | OS | 75 | 32 | 43 | M | H VS L | HR | 1.14 | 0.7 | 1.86 | 0.6 | |||||
PFS | H VS L | HR | 1.487 | 0.8933 | 2.4752 | 0.127 | |||||||||||
Rahbar,A. | 2012 | Sweden | GBM | IHC | IEA | OS>18 months | 80 | 19 | 61 | M | H VS L | Odds | 6.604 | 1.359 | 32.094 | 0.019 | |
LA | OS>18 months | 80 | 19 | 61 | M | H VS L | Odds | 3.758 | 0.425 | 3.758 | 0.67 | ||||||
Adnan Ali, S. M. | 2019 | HPV | GBM | PCR | GP5、6 | OS | 112 | 31 | 81 | M | P VS N | HR | 0.913 | 0.407 | 2.047 | 0.825 | |
Vidone, M. | 2014 | GBM | PCR | MY/GP | OS | 52 | 12 | 40 | M | P VS N | HR | 2.48 | 0.99 | 6.24 | 0.45 | ||
Wang, Z. | 2017 | China | SV40 | LGG | PCR | A | OS | 172 | 40 | 132 | M | P VS N | HR | 2.935 | 1.4894 | 5.7837 | 0.0019 |
WMSV | LGG | PCR | B | OS | 172 | 25 | 147 | M | P VS N | HR | 2.109 | 1.0662 | 4.1715 | 0.032 | |||
CMV | glioma | PCR | OS | 138 | 8 | 130 | U | P VS N | HR | 2.88 | 0.17 | 48.7906 | 0.4638 | ||||
K113 | glioma | PCR | OS | 308 | 28 | 280 | U | P VS N | HR | 0.6216 | |||||||
Crawford, J. R. | 2009 | USA | HHV-6 | glioma | IHC | gp116 | OS | 173 | 65 | 108 | U | P VS N | HR | 1.07 | 0.76 | 1.5 | 0.6983 |
IHC | p41 | OS | 167 | 53 | 114 | U | P VS N | HR | 1.25 | 0.8 | 1.95 | 0.3271 | |||||
Crawford, J. R. | 2009 | USA | HHV-6 | glioma | IHC | Gp116/64/54 | OS | 130 | 42 | 88 | M | P VS N | median survival time | 3.08 vs 3.25 | years | 0.245 | |
PFS | 130 | 42 | 88 | M | P VS N | medain PFS | 2.67 vs 2.25 | years | 0.653 |